Sex difference in circulating PCSK9 and its clinical implications
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the degradation of LDL receptors (LDLRs). Beyond the regulation of circulating LDL-C, PCSK9 also has direct atherosclerotic effects on the vascular wall and is associated with coronary plaque inflammation. Interestingly, emerging data show that women have higher circulating PCSK9 concentrations than men, suggesting that the potential roles of PCSK9 may have different impacts according to sex. In this review, we summarize the studies concerning sex difference in circulating levels of PCSK9. In addition, we report on the sex differences in the relations of elevated circulating PCSK9 levels to the severity and prognosis of coronary artery disease, the incidence of type 2 diabetes mellitus, and neurological damage after cardiac arrest and liver injury, as well as inflammatory biomarkers and high-density lipoprotein cholesterol (HDL-C). Moreover, sex difference in the clinical efficacy of PCSK9 inhibitors application are reviewed. Finally, the underlying mechanisms of sex difference in circulating PCSK9 concentrations and the clinical implications are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“PCSK9 inhibitors could lead to significant LDL-C reductions in high-risk patients, and they have shown a favorable safety profile in recent clinical trials (Robinson et al., 2015; Sabatine et al., 2017).”
BackgroundMadsen, C. M., Varbo, A., & Nordestgaard, B. G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx163 · Cited by 715
Gender differences in glucose homeostasis and diabetes
Mauvais-Jarvis, F. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.08.016 · Cited by 377 · cited 1×
“Circulating PCSK9 levels change in women depending on their reproductive stage of life, and serum estrogen is inversely correlated with circulating PCSK9 levels, while in men, serum testosterone is not correlated with circulating PCSK9 levels (Ooi et al., 2015; Mauvais-Jarvis, 2018).”
BackgroundNanna, M. G., Wang, T. Y., Xiang, Q., Goldberg, A. C., Robinson, J. G., Roger, V. L., Virani, S. S., Wilson, P. W. F., Louie, M. J., Koren, A., et al. (2019) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005562 · Cited by 313
Qi, Z., Hu, L., Zhang, J., Yang, W., Liu, X., Jia, D., Yao, Z., Chang, L., Pan, G., Zhong, H., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046290 · Cited by 268 · cited 1×
“PCSK9 was found to aggravate microvascular obstruction and promote myocardial infarction (MI) expansion post-MI in MI mouse models, and a PCSK9 inhibitor weakened the enhanced platelet aggregation and ameliorated microvascular obstruction (Qi et al., 2021).”
BackgroundSafety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., & Xu, B. (2015) · BMC Medicine · doi:10.1186/s12916-015-0358-8 · Cited by 260
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181 · cited 8×
“An animal model evaluating the sex-specific distribution of low-density lipoprotein receptors (LDLRs) shows that the absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of LDLRs, suggesting that PCSK9 and estrogen may act as molecular regulators of cholesterol homeostasis, and PCSK9 inhibit…”
BackgroundInfluentialSimeone, P. G., Vadini, F., Tripaldi, R., Liani, R., Ciotti, S., Di Castelnuovo, A., Cipollone, F., & Santilli, F. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.632655 · Cited by 3
Cited by
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab
Fogacci, F., Yerlitaş, S. İ., Giovannini, M., Zararsız, G., Lido, P., Borghi, C., & Cicero, A. F. G. (2023) · Biomedicines · doi:10.3390/biomedicines11123271 · Cited by 15
“A tentative explanation for this observation could lie in the different PCSK9 concentrations between sexes [10], since large-scale clinical studies involving the collection of blood samples for the centralized measurement of PCSK9 showed that women have higher circulating PCSK9 than men [11].”
BackgroundJin, P., Ma, J., Wu, P., Yan, R., Bian, Y., Jia, S., Zheng, Q., & Ma, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117031 · Cited by 9
Metadata
- Authors
- Jia, F., Fei, S.-F., Tong, D.-B., Xue, C., & Li, J.-J.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-09-07
- Volume
- 13
- Pages
- 953845-953845
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4297256839
- Cited by
- 40
- References
- 10
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.